Henry Schein, Inc. (HSIC) EBITDA Margin: 7.63%
Is Henry Schein, Inc.’s EBITDA margin high or low?
Henry Schein, Inc.'s EBITDA margin of 7.63% is in line with its 5-year average of 7.62%, around the middle of its 5-year range (7.11%–8.61%).
As of Tuesday, June 23, 2026. 1.33% above its 12-month average of 7.53%.
HSIC EBITDA Margin Chart
HSIC Average EBITDA Margin Chart
HSIC Current vs Average EBITDA Margin Chart
HSIC EBITDA Margin Metrics
EBITDA MARGIN
7.63%
EBITDA MARGIN AVG TTM
7.53%
EBITDA MARGIN AVG 3Y
7.47%
EBITDA MARGIN AVG 5Y
7.62%
EBITDA MARGIN AVG 10Y
7.81%
EBITDA MARGIN AVG 15Y
8.18%
EBITDA MARGIN AVG 20Y
8.10%
CURRENT VS TTM AVG
+1.33%
CURRENT VS 3Y AVG
+2.07%
CURRENT VS 5Y AVG
+0.20%
CURRENT VS 10Y AVG
-2.36%
CURRENT VS 15Y AVG
-6.74%
CURRENT VS 20Y AVG
-5.81%
HSIC Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Henry Schein, Inc. (HSIC) | $8.96B | 7.63% | 7.53% | 7.47% | 7.62% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.75B | 10.23% | 12.29% | 18.59% | 20.64% |
| Tempus AI, Inc. (TEM)vs › | $8.35B | -17.48% | -52.76% | -51.11% | -63.28% |
| Baxter International Inc. (BAX)vs › | $10.15B | 6.81% | 8.65% | 4.13% | 9.00% |
| Oscar Health, Inc. (OSCR)vs › | $7.63B | -3.34% | -1.19% | -4.96% | -19.15% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.60B | 48.39% | -17.53% | -54.94% | 28.49% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -7.64% | -4.75% | -0.21% | 1.54% |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.48B | 7.60% | 6.80% | 0.29% | -7.92% |
| Revvity, Inc. (RVTY)vs › | $11.05B | 23.20% | 26.85% | 28.84% | 31.56% |
| Align Technology, Inc. (ALGN)vs › | $12.44B | 18.98% | 19.70% | 20.24% | 21.46% |
Margin Comparison
Gross Margin
29.7%
EBITDA Margin
7.6%
Operating Margin
5.6%
Net Margin
3.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Henry Schein, Inc. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Henry Schein, Inc. EBITDA Margin FAQ
- What is the EBITDA margin for Henry Schein, Inc. (HSIC)?
- The EBITDA margin for HSIC stock is 7.63%.
- Is Henry Schein, Inc.'s EBITDA margin high or low?
- Henry Schein, Inc.'s EBITDA margin of 7.63% is in line with its 5-year average of 7.62%, around the middle of its 5-year range (7.11%–8.61%).
- What is the TTM average EBITDA margin for Henry Schein, Inc. (HSIC)?
- The TTM average EBITDA margin for HSIC stock is 7.53%.
- What is the 3Y average EBITDA margin for Henry Schein, Inc. (HSIC)?
- The 3Y average EBITDA margin for HSIC stock is 7.47%.
- What is the 5Y average EBITDA margin for Henry Schein, Inc. (HSIC)?
- The 5Y average EBITDA margin for HSIC stock is 7.62%.
- What is the 10Y average EBITDA margin for Henry Schein, Inc. (HSIC)?
- The 10Y average EBITDA margin for HSIC stock is 7.81%.
- What is the 15Y average EBITDA margin for Henry Schein, Inc. (HSIC)?
- The 15Y average EBITDA margin for HSIC stock is 8.18%.
- What is the 20Y average EBITDA margin for Henry Schein, Inc. (HSIC)?
- The 20Y average EBITDA margin for HSIC stock is 8.10%.
Henry Schein, Inc. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-27 | 7.63% |
| 2024-12-28 | 7.43% |
| 2023-12-31 | 7.11% |
| 2022-12-31 | 7.73% |
| 2021-12-31 | 8.61% |
| 2020-12-31 | 7.18% |
| 2019-12-31 | 9.17% |
| 2018-12-31 | 5.73% |
| 2017-12-31 | 8.58% |
| 2016-12-31 | 8.27% |
| 2015-12-31 | 8.52% |
| 2014-12-31 | 8.54% |
| 2013-12-31 | 8.58% |
| 2012-12-31 | 8.51% |
| 2011-12-31 | 8.39% |
| 2010-12-31 | 8.47% |
| 2009-12-31 | 8.53% |
| 2008-12-31 | 7.95% |
| 2007-12-31 | 8.13% |
| 2006-12-31 | 7.52% |
| 2005-12-31 | 7.17% |
| 2004-12-31 | 6.59% |
| 2003-12-31 | 8.02% |
| 2002-12-31 | 7.97% |
| 2001-12-31 | 7.17% |
| 2000-12-31 | 6.78% |
| 1999-12-31 | 6.45% |
| 1998-12-31 | 6.05% |
| 1997-12-31 | 5.16% |
| 1996-12-31 | 6.71% |
Related Metrics
About Henry Schein, Inc.
Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repair services. Furthermore, it distributes a broad range of medical supplies, including pharmaceuticals (both branded and generic), vaccines, surgical instruments, diagnostic kits, infection prevention solutions, imaging products, equipment, and nutritional supplements. The Technology and Value-Added Services segment focuses on empowering practices with advanced software, technology, and supplementary solutions. This includes specialized practice management software systems tailored for both dental and medical professionals. Beyond software, it delivers crucial value-added practice support services, such as non-recourse financial assistance, electronic services, comprehensive technology and network infrastructure support, hardware services, ongoing professional development programs, and expert consulting. Established in 1932, Henry Schein, Inc. maintains its corporate headquarters in Melville, New York.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Andrea Albertini